First-line treatment of advanced clear-cell renal cell carcinoma (RCC) now rests on immune checkpoint inhibitor (ICI)-based combination therapy, and every major guideline has converged on that architecture. Yet none supplies a rule for choosing among the doublets: there is no head-to-head phase 3 comparison of the recommended regimens, and no validated predictive biomarker assigns a given patient to a given combination. OncoDaily’s recent review sets out that selection problem, together with the post-IO and HIF-2α data now reshaping it.
That review closes on a different question: how are these decisions made across health systems in which access to combination biologics, monitoring infrastructure and supportive care varies considerably? That question is the subject of this article, and it is the axis along which the evidence is thinnest. It also determines whether a category 1 recommendation becomes delivered care or remains an endorsement.
Ahead of VIRO 2026 – Global Voices in Renal Oncology, this article examines what the major guidelines recommend for the patient who cannot receive the standard combination, how resource-stratified instruments handle kidney cancer, and why stratifying drugs has proved far easier than stratifying everything required to give them safely
What the Guidelines Recommend and What They Say About the Exception
The major guidelines are broadly aligned on first-line treatment. The differences become more relevant when an ICI-based combination cannot be used, whether because of comorbidity, toxicity, contraindication, or access.
NCCN. The NCCN Guidelines for Kidney Cancer (Version 1.2027) list four preferred category 1 ICI-based combinations for treatment-naive advanced clear-cell RCC: axitinib plus pembrolizumab, cabozantinib plus nivolumab, ipilimumab plus nivolumab, and lenvatinib plus pembrolizumab. Cabozantinib and other VEGFR TKIs remain options in selected circumstances. In the 2026 update, ipilimumab plus nivolumab was upgraded from category 2A to category 1 preferred, while several combinations used after prior immunotherapy were downgraded from category 2A to category 2B (Haas NB, NCCN Annual Conference, 2026).
ESMO. The ESMO Clinical Practice Guideline similarly places PD-1-based combinations at the center of first-line treatment, either with a VEGFR-targeted agent or with CTLA-4 blockade. Importantly, ESMO also addresses patients for whom immunotherapy is contraindicated or simply unavailable. In these settings, sunitinib, pazopanib, or tivozanib may be used, with cabozantinib an alternative for patients with IMDC intermediate- or poor-risk disease (Powles T et al., Annals of Oncology, 2024).
ASCO. The ASCO guideline retains a stronger role for IMDC risk in treatment selection. Patients with favourable-risk disease who require systemic therapy may receive an ICI plus a VEGFR TKI, while those with intermediate- or poor-risk disease should generally receive combination therapy. ASCO also leaves room for monotherapy in selected patients, stating that either an ICI or a VEGFR TKI may be considered when comorbidity makes standard combinations difficult to use (Rathmell WK et al., Journal of Clinical Oncology, 2022). A subsequent Rapid Recommendation Update advises against adding cabozantinib to nivolumab plus ipilimumab in the first-line setting (Singer EA et al., Journal of Clinical Oncology, 2023).
EAU. The EAU Renal Cell Carcinoma Guideline is particularly clear about the alternative pathway. Sunitinib or pazopanib carry a strong recommendation for patients of any IMDC risk group who cannot receive or tolerate an ICI. Cabozantinib is recommended for the same situation in intermediate- or poor-risk disease (Bex A et al., European Urology, 2025).
The practical distinction is important. ESMO explicitly recognizes nonavailability of immunotherapy, while EAU focuses on patients who cannot receive or tolerate it. Both therefore provide evidence-based alternatives when the preferred ICI-based strategy is not possible.
But the reason for using that alternative matters. If a VEGFR TKI is chosen because immunotherapy is clinically unsuitable, that is a treatment decision based on the patient. If it is chosen because immunotherapy is unavailable or inaccessible, that is an access-driven compromise. The regimen may still be guideline-supported, but it should not be presented as biologically or clinically equivalent to the preferred first-line combination. That distinction should be documented clearly.
Sequencing Strategy Assumes a Sequence
Guidelines for advanced RCC are built around treatment sequencing. In practice, however, many patients never reach the next line.
A Dutch nationwide registry analysis followed 2,621 patients with synchronous metastatic RCC diagnosed between 2018 and 2022. Overall, 55% received systemic therapy, while 37% received best supportive care alone. Among patients who started first-line systemic treatment in 2019–2020, only 32% went on to receive a second line, and just 10% reached a third line (Yildirim H et al., European Urology Open Science, 2025).
These numbers change how first-line treatment should be viewed. If only a minority of patients will receive subsequent therapy, the first line is not simply the beginning of a longer sequence. For many patients, it will represent most, or all, of their systemic treatment.
That makes the choice of first-line therapy especially important. The question is no longer only which strategy performs best across several lines of treatment, but which treatment is most likely to deliver meaningful benefit now, in the setting in which the patient is actually being treated.
In that context, deliverability, tolerability, access to monitoring, and the ability to manage toxicity are not secondary considerations. They directly influence whether an effective regimen can be given safely, maintained long enough, and ultimately provide the benefit seen in clinical trials.
Three Global Instruments, and What They Cover in Kidney Cancer
The NCCN Framework for Resource Stratification adapts NCCN recommendations across basic, core, and enhanced resource settings. The levels are cumulative, and higher-level recommendations remain visible, so the framework functions as a roadmap for system development rather than simply a list of what cannot be offered (Carlson RW et al., JNCCN, 2016; Koh WJ et al., Cancer, 2020).
ASCO also publishes resource-adapted Global Guidelines across several common cancers and supportive-care areas, but kidney cancer is not currently included (Aziz Z et al., JCO Global Oncology, 2024).
The WHO Model List of Essential Medicines addresses access from a different angle, guiding national procurement and reimbursement priorities. In its 24th edition, released in September 2025, WHO added pembrolizumab for selected first-line indications in metastatic cervical, colorectal, and non-small cell lung cancer, but no RCC indication was included.
For kidney cancer, the gap is clear. Among the major contemporary international frameworks discussed here, NCCN is the only one with a kidney-specific resource-stratified pathway. An Asian Oncology Summit consensus proposed a four-level model in 2012, but it predates ICI-based doublets and HIF-2α therapy (Chiong E et al., Lancet Oncology, 2012).
Neither ESMO nor EAU currently stratifies RCC recommendations by resource level. ESMO-MCBS measures magnitude of clinical benefit, but that is not the same as assessing whether a regimen can realistically be delivered within a given health system.
That distinction matters because modern RCC treatment depends on far more than drug availability. Infusion capacity, toxicity monitoring, imaging, laboratory support, specialist review, and access to subsequent therapy all shape what can actually be delivered. For such an infrastructure-dependent disease, the lack of an updated cross-guideline resource-adapted framework remains an important gap.
Where Stratification Stops: Three Test Cases from the Past Two Years
An ICI combination is not just a drug choice; it is a service that depends on how treatment is delivered, where the patient lives, and whether toxicity can be recognised and managed.
Route of administration. Subcutaneous nivolumab was approved following CheckMate-67T in advanced clear-cell RCC, and subcutaneous pembrolizumab followed across solid tumours in 2025. In a prospective time-and-motion study, subcutaneous pembrolizumab reduced active health-care professional time by 45.6%, chair time by 49.6%, and treatment-room time by 47.4% compared with intravenous administration (De Cock E et al., Advances in Therapy, 2025).
For a centre limited by nursing time and infusion capacity, that difference may matter as much as the choice between regimens. Yet most resource frameworks stratify drugs, not routes of administration.
Where the patient lives. Belzutifan appears relatively easy to deliver because it is oral, but geography may change its safety profile. In a retrospective cohort of 34 patients with metastatic RCC treated at a mean altitude of 1,457 metres, hypoxia occurred in 88% and 82% required home oxygen. In LITESPARK-005, the corresponding rates were 14.5% and 10.2% (Seidel A et al., Journal of Clinical Oncology, 2026).
The finding is hypothesis-generating, but it highlights a broader point: an oral drug can still require substantial monitoring. Belzutifan requires haemoglobin and oxygen-saturation assessment, dose modification for toxicity, and access to transfusion or supplemental oxygen when needed.
That requirement is becoming more relevant as belzutifan moves earlier in RCC treatment. LITESPARK-011 established a belzutifan-containing combination after anti–PD-(L)1 therapy, while LITESPARK-022 moved belzutifan into the adjuvant setting. Pembrolizumab plus belzutifan improved disease-free survival over pembrolizumab alone, with grade 3 or higher anaemia in 12.1% and hypoxia in 4.6% (Choueiri TK et al., New England Journal of Medicine, 2026). The combination was subsequently approved by the FDA in June 2026 for selected patients with clear-cell RCC after nephrectomy.
Recognition and management of toxicity. This may be the least visible resource requirement of all. Safe ICI delivery depends on more than access to the drug itself. It requires clinicians who can recognise immune-related adverse events, rapid access to corticosteroids and second-line immunosuppression, specialist input when needed, and clear pathways for managing toxicity outside routine clinic hours.
Rare events such as immune-related myocarditis make this particularly important. A framework that categorises an ICI doublet as deliverable without also considering the system required to manage its complications may overestimate what that setting can safely provide.
The Rest of the Apparatus
Drug access is only one part of deliverability. Three other components matter across every resource level.
Diagnostics. Guidelines assume histological confirmation and accurate IMDC classification. The laboratory tests themselves are relatively inexpensive; the larger constraint is access to reliable pathology, timely reporting, and expertise in contemporary renal tumour classification.
Imaging and response assessment. Modern treatment sequencing also assumes that response can be assessed at appropriate intervals. Where CT or MRI access is limited, ineffective treatment may be continued longer than intended, while a beneficial change in therapy may be delayed. This is one way trial efficacy can lose ground in routine practice.
Supportive and palliative care. Bone-directed therapy, palliative radiotherapy, symptom control, and reliable opioid access remain essential at every tier. In many countries, however, opioid availability is still limited by regulatory, logistical, or supply barriers.
What Changes When the Drug Gets Cheaper
The access problem may change substantially over the next few years. WHO modelling anticipates biosimilar entry from 2028 onward, depending on the molecule and jurisdiction, and estimates that pembrolizumab prices could fall by as much as 60% (WHO, 2025).
That matters for RCC because pembrolizumab already sits within two category 1 first-line combinations. As prices fall, the limiting factor may increasingly shift from whether the drug can be purchased to whether the system can deliver it safely.
Infrastructure, however, takes longer to build than a formulary changes. Immune-related adverse-event pathways, out-of-hours escalation, specialist support, reliable imaging, and toxicity monitoring cannot be created overnight once a biosimilar becomes affordable.
The years before broader biosimilar entry therefore represent an opportunity. Health systems can use that period to build the services required to convert lower drug prices into better outcomes. Resource-stratified guidance could help define which elements should be built first
Practical Implications
Use the tier that matches the setting. A published, evidence-based standard adapted to available resources is stronger than informal de-escalation at the bedside. Resource stratification turns an individual compromise into a transparent clinical pathway.
Use the framework for advocacy. A ranked list of what should be funded next can be useful in formulary and health-system discussions. It makes the request concrete: this is the next resource required, this is the benefit it is expected to add, and this is why it should come before the next one.
Generate evidence locally. Most trials informing RCC treatment were conducted in high-resource settings. Real-world effectiveness, toxicity, and treatment attrition in more constrained systems remain poorly characterised.
This is where local data become particularly important. Retrospective cohorts from low- and middle-income settings can identify where treatment delivery differs, which toxicities become more difficult to manage, and how often patients actually reach later lines of therapy. In resource-stratified oncology, those data are not secondary evidence. They are part of what is needed to build the framework itself.
A Floor, Not a Ceiling
Resource-stratified guidelines can be mistaken for a way of formalising unequal care. But the alternative is not that every patient receives the highest standard. In many constrained settings, the alternative is simply that each clinician makes the same compromises without a shared framework.
No guideline can eliminate the distance between a recommendation and its delivery. What resource stratification can do is make that gap visible, define what is feasible now, and identify what needs to be built next.
For advanced RCC, that work should extend beyond the drug itself. Route of administration, monitoring capacity, toxicity management, specialist support, imaging access, and even the geography of the patient can all determine whether a recommended treatment is genuinely deliverable.
The goal of resource stratification should therefore be to establish a floor, not a ceiling: a safe, evidence-based standard for the setting that exists today, while keeping the path toward better care clearly visible.
These are among the questions on the agenda at VIRO 2026 – Global Voices in Renal Oncology, taking place virtually on September 10–11, 2026.
Written by Ahmed Elalfy, MD, PhD
